Qualigen Therapeutics Inc (QLGN) Quote

QLGN new 52 week low

$QLGN - 👆Up 12.3% Pre-Market/ Current Price $1.31
Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

2nd day above $1,8 more,prevents compliance issue,would be good timing for news

watch for mid day push,had a good mid+end fri.,accumulation continuing 3 days now,no mm games so far

events mid year> https://finance.yahoo.com/news/qualigen-therapeutics-chief-executive-officer-140500414.html

not optionable,shares to short dropping,ZERO BORROW in sight,bid building,supply is half of demand thru 1.18

9Xs rel.buy vol.,target $22.50,sales up 128%,107day uptrend(breakout today)

and now down 18%. Form S 3 effect of offering

$QLGN: BOooommmmmmmmmmm....... now 1.85


How did you know ????


Nice call.............. she flyingggggggggg now.


Up 30% on the day


GO $QLGN

Looking like something is brewing again, that could put the corrupt naked shorters on their toes, would think twice about shorting this one right now.

Sure would be nice if it did a repeat of those recent highs, and ripped the corrupt shorts a new one.

4 Swing Trade Ideas #LGVN ?? #CRTX ?? #GRTX ?? #QLGN ?? Technical analysis with entry and exit!

QLGN Chart

Hoping this time its real and not pump and dump

Ofcourse imo??

Pump and then the dump

$9.00 PT put on it today
Qualigen Therapeutics, Inc. ("QLGN") is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation.

Zacks Small-Cap Research Report Has Issued a $9 Price Target.
Shorts better close it out, next week could be a lot more of pain if they don't.

They sure are loading them up today.

20% of the float short, and better be covering or loading the Jan 21 calls to save their butts the last run up went over$3.00.

someone still buying $2.50 options maybe a PR will drop

There is always a bunch of dirty SOB's that know something about what's coming, and it gets leaked, there are just too many times that these kind of stocks have big runs and than many times get faded before offer news hits the wire, if that was the case here, it looks like that not many knew about it, it was trading really well until they dropped the toxic bomb on share holder's, those with stop orders in place, and those with set alerts to certain kind of news, and algos trading were able to get out fast.

I doubt it. They either sold because they thought it was time to take profits or they're lying about selling. It'll be easy to tell. They'll be pumping the shiatzu out of this stock while it's down.

Those that sold at 2.97 might have had "insider knowledge," right?

Pure mumbo-jumbo to give the impression that this is somehow "good". The drop in price tells the full story.

Petros Pharma, Qualigen see dramatic rises amid social media buzz, short squeezes

Nov. 29, 2021 2:34 PM ETQualigen Therapeutics, Inc. (QLGN), PTPIBy: Jonathan M Block, SA News Editor1 Comment

?

Vertigo3d/E+ via Getty Images

Microcaps Petros Pharmaceuticals (PTPI +104.3%) and Qualigen Therapeutics (QLGN +24.4%) are among the best performing biotechs today as discussion of the companies accelerates on social media and potential short squeezes taking place.

Message volume on Stocktwits for Petros is up 94% more than average. Stock volume in Petros, as of 2:30 PM, is ~201.6M shares. Average daily volume is 6.6M shares.

By comparison, Qualigen is seeing a more modest upswing. Volume as of 2:30 PM is ~35.8M shares. Average daily volume is ~5.3M shares.

Petros shares surged last week after announcing its annual shareholder meeting for next month.

Now Read: Qualigen Therapeutics EPS beats by $0.11, misses on revenue

You would surely like to think a lot more than a buck fifty, and laugh at today's panic bag holders that ran for the hills on the offer news.

If the institutional investors buy it for $1.50, what do they expect to get when they sell the shares?

Could possibly be a good bounce once all the panicked bag holders are gone, after today's sell down after the offering news hit, looks like on the volume that many of them took their bag loss and hit the road.

What about this?

"The offering is conditioned upon the Company receiving a waiver from a prior investor of certain rights, inclusive of a 30-day lock-up of common stock by such investor at prices below $3.00 per share and an agreement with such investor to reprice previously issued warrants to purchase up to approximately 5.4 million shares of common stock at a revised exercise price of $2.00 per share and a six-month extension of the warrants’ respective termination dates."

It means they're diluting shares.

Does that mean that there will be plenty of shares available at a price around $1.50 in 2 days?

QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
Download as PDFNOVEMBER 29, 2021 3:50PM EST
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company’s common stock at a purchase price of $1.50 per share pursuant to a registered direct offering. The closing of the offering is expected to occur on or about December 1, 2021, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

The offering is conditioned upon the Company receiving a waiver from a prior investor of certain rights, inclusive of a 30-day lock-up of common stock by such investor at prices below $3.00 per share and an agreement with such investor to reprice previously issued warrants to purchase up to approximately 5.4 million shares of common stock at a revised exercise price of $2.00 per share and a six-month extension of the warrants’ respective termination dates.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-232798) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Qualigen Therapeutics, Inc.

Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics for 20 years. Our therapeutics pipeline includes cancer drug compounds such as QN-247 and RAS-F. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.

Qualigen Forward-Looking Statements

This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates and the consummation of the offering. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully consummate the offering, develop any drugs (including QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-247 and RAS-F) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (including Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-247 and RAS-F); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:
For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free - U.S. & Canada
dk@atlcp.com

Tony Schor
Investor Awareness, Inc.
(847) 971-0922
tony@investorawareness.com

What does that mean?

what happened here?

Stock offering Pricks

Oh that offering...

MF .... 2.70 down to 1.70 last ten mins BS

I have very few strikes and first one is 18 days out. What are you looking at that it’s going nuts?

options going nutso so somone knows something

Drop that Covid PR and this hits $5

QLGN chart

QLGN - Tuesday Rundown, Wednesday Expectations

zacks small cap research with 9 price target pump news

Any news? On this pop

I'm adding here. QLGN has had no news and nothing but negativity. I've done dumber things.

Do something.

Another price target from a Brokerage for $6.50.

Great day!

QLGN time to load

GidDy uP QLGN...